Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23643426 | 1.00 | CRBN (0.43) | CRBNDDB1HRH3SIGMAR1APP | |
| SCHEMBL23643427 | 1.00 | CRBN (0.43) | CRBNDDB1HRH3SIGMAR1APP | |
| SCHEMBL23919127 | 0.95 | CRBN (0.42) | CRBNDDB1SIGMAR1PARP1POLB | |
| SCHEMBL23643615 | 0.95 | CRBN (0.42) | CRBNDDB1SIGMAR1PARP1POLB | |
| SCHEMBL23919128 | 0.95 | CRBN (0.42) | CRBNDDB1SIGMAR1PARP1POLB | |
| SCHEMBL23643595 | 0.88 | CRBN (0.43) | CRBNDDB1HRH3POLBKMT2A | |
| SCHEMBL23919375 | 0.88 | CRBN (0.43) | CRBNDDB1HRH3POLBKMT2A | |
| SCHEMBL23643708 | 0.88 | CRBN (0.43) | CRBNDDB1HRH3POLBKMT2A | |
| SCHEMBL23635011 | 0.87 | CRBN (0.42) | CRBNDDB1HRH3SIGMAR1APP | |
| SCHEMBL23634906 | 0.87 | CRBN (0.42) | CRBNDDB1HRH3SIGMAR1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319330-B2 | Tricyclic furan-substituted piperidinedione compound | MEDSHINE DISCOVERY INC. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210317138-A1 | TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319330-B2 | Tricyclic furan-substituted piperidinedione compound | CRBN, PFDN1, CLNS1A | CRBN 1/4885DDB1 833/4885HRH3 3754/4885 |
| US-20210317138-A1 | TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND | CRBN, PFDN1, CLNS1A | CRBN 1/4885DDB1 833/4885HRH3 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.